Webinar: “Orphan Medicinal Products Old myths and new realities” - 23rd June 2021
Robin Lachmann - Presentation
37 mins
Sandra Sirrs - Presentation
30 mins
Q&A Session
24 mins
Full Webinar
94 mins
Webinar Summary & Objectives:
- Describe the increasing impact of OMPs on healthcare costs
- Describe societal challenges that may complicate efforts to control drug prices for OMPs
- Describe ways in which development programs and market access for OMPs differ from those for common disease drugs
WEBINAR: “Childhood Hypoglycaemia why worry? ….” - 12th May 2021
SPEAKERS:
+ Dr Indi Banerjee, Consultant in Paediatric Endocrinology at Manchester University NHS Foundation Trust
+ Prof. John Walter, Honorary Clinical Professor, Inherited Metabolic Medicine Developmental Biology and Medicine, School of Medical Sciences, University of Manchester, UK
+ Dr Elisabeth Jameson, Former Consultant in Paediatric Inborn Errors of Metabolism Manchester Centre for Genomic Medicine Manchester Universities NHS Foundation Trust
WEBINAR OBJECTIVES:
- What is the emergency management of hypoglycaemia? What are the important initial investigations?
- What are the causes of hyperinsulinism in childhood? How do they present and how are they diagnosed and managed?
- Which inherited metabolic disorders present with hypoglycaemia in childhood? How do they present and how are they diagnosed and managed?
What's new in Neurometabolic Disease: Webinar - 17th February 2021
SPEAKERS:
+ Angeles García-Cazorla, Sant Joan de Déu Hospital, Barcelona
+ Fanny Mochel Pitié-Salpêtrière Hospital, Paris
WEBINAR OBJECTIVES:
When to consider a metabolic disease in patients with neurological signs?
How to diagnose such diseases?
What treatment and family care shall be initiated without delay?
SUMMARY:
The webinar will be split into a paediatric and adult perspective with clinical cases illustrating new neurometabolic diseases described in the last 3-4 years, with biomarkers, and the growing place of these disorders in adult neurology.
Each clinical case will introduce important aspects to be discussed such as; differential diagnosis, the hard pathway through discovery and validation of new disorders, new available biomarkers and the opportunities for new treatments.